This WG will investigate how to optimally stratify patients before treatment (“which therapeutic antibody to use for a particular patient”) and at start of treatment (“which therapeutic antibody dose to use for a particular patient”).
This WG will investigate the individualised treatment optimisation of therapeutic antibodies in chronic inflammatory diseases. More specifically, this WG will focus on deriving therapeutic windows for different therapeutic…
This WG will be responsible for several overarching activities needed for an optimal functioning of WG1 and WG2. First, this WG will investigate and implement measures for the harmonisation and standardisation of TDM assays to be able to compare…
The ultimate goal of the WG4 is to increase the awareness of the importance of the cost-effectiveness of TDM of inflammatory diseases. In addition, the WG will encompass the acceptability and affordability aspect of TDM by both patients and caregivers…
This WG focuses on coordinating all communication and dissemination activities of the Action via the website, social media, open access journals, etc. The Action’s website and social media serve as the main communication channels between Action members…